Compare Travere Therapeutics Inc. Common Stock (TVTX) vs US Foods Holding Corp. Common Stock (USFD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs US Foods Holding Corp. Common Stock — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while US Foods Holding Corp. Common Stock trades at $98.45 (market cap $21.18B). The key difference: US Foods Holding Corp. Common Stock is far larger — about 4.3× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is more actively traded (1,668,577 versus 1,065,315). Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and US Foods Holding Corp. Common Stock for 6 Days on average.
| TVTX | USFD | |
|---|---|---|
Market Cap | $4.88B | $21.18B |
Volume | 1,668,577 | 1,065,315 |
Sector | Health | Consumer Staples |
52-Week High | $67.52 | $110.94 |
52-Week Low | $26.79 | $70.05 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $5.01B | $26.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
US Foods (USFD) trades at $97.91, showing modest daily gains of 0.21%. The stock maintains a bullish technical trend with strong moving average support and trades near key resistance at $98. Fundamentally, the company demonstrates solid revenue growth with $39.42B in 2025 sales and improving profitability, though net margins remain thin at 1.81%. Recent business developments include new product launches and conference participation, signaling ongoing operational momentum.
The outlook remains positive with analyst consensus strongly favoring Buy ratings (73%) and a $117 price target suggesting 19% upside. Key opportunities include margin expansion and market share gains, while risks involve competitive pressures and execution challenges in a low-margin industry. The combination of technical strength, fundamental improvement, and Wall Street support positions USFD favorably for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About US Foods Holding Corp. Common Stock
US Foods distributes food and related products to foodservice operators. Its customers include restaurants, healthcare providers, hospitality businesses, government institutions, and educational organizations.
Read more on USFD →
